Sharath Chandra Macha says systems should work the way people think. If you need training just to do simple stuff, ...

Even upbeat guidance from ServiceNow wasn’t enough to shake negative software sentiment. Software stocks have taken a beating in recent months, reflecting questions about whether artificial ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today announced financial results for its fourth quarter ended December 31, 2025, with ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260128041272/en/ The articles, information, and content displayed on this webpage ...

SANTA CLARA, Calif., January 28, 2026--ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today announced financial results for its fourth quarter ended December 31, 2025, with ...

Anthropic’s move into the JavaScript ecosystem surprised almost everyone. Buying a popular runtime isn’t just a tooling decision, it’s a strategic one. JavaScript sits at the center of modern software ...

IIM Indore is inviting applications for its two-year Master of Management Studies (MMS) program, specifically tailored for working professionals. The deadline for applications is February 10, 2026.

With software stocks badly trailing the rest of the tech sector of late, investors told CNBC that they're buying the dip and predicted a flurry of deals. Shares of Salesforce, ServiceNow and Adobe ...

OpenAI and enterprise software firm ServiceNow have forged a partnership to integrate advanced AI models and agents into ServiceNow's corporate workflows, enhancing capabilities in voice customer ...

ServiceNow signed a three-year deal with OpenAI to use its intelligence models to offer AI agents to customers. ServiceNow will add OpenAI's GPT-5.2 into its enterprise platform. ServiceNow is in the ...

SAN DIEGO , CA, UNITED STATES, January 12, 2026 /EINPresswire.com/ — Options For All, a California-based nonprofit dedicated to inclusive employment, announced ...

The FDA postponed reviews for two drugs in the Trump administration's fast-track program due to safety and efficacy concerns. A patient death and adverse events raised red flags about the medicines' ...